FORT LAUDERDALE, Fla., Nov. 25 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., announced today that Schering AG has completed the evaluation of their new fluorescence dyes with three modified CT Laser Mammography systems. The loaned systems had been modified to Schering AG’s specifications and will be returned to IDSI.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
IDSI believes that fluorescence dyes and other vasoactive agents may help improve the cancer detection accuracy of Laser Breast imaging. The company will continue research in this area.
The CT Laser Mammography (CTLM(R)) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: http://www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filing with the Securities and Exchange Commission.
Investor Relations: Rick Lutz
404-261-1196 lcgroup@mindspring.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.
CONTACT: Investor Relations: Rick Lutz for Imaging Diagnostic Systems,Inc., +1-404-261-1196, lcgroup@mindspring.com
Web site: http://www.imds.com/
